ClinicalTrials.gg
CompletedNCT05887908Integral-1Updated Dec 24, 2025Results posted

Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis

A Phase 3 interventional study of co-administration of cefepime and nacubactam and co-administration of aztreonam and nacubactam in Complicated Urinary Tract Infection, Acute Pyelonephritis and cUTI, sponsored by Meiji Seika Pharma Co., Ltd.. Completed at 61 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Meiji Seika Pharma Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
614
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Phase 3 study to evaluate the efficacy and safety of cefepime/nacubactam or aztreonam/nacubactam compared to imipenem/cilastatin in the treatment of complicated urinary tract infections (cUTI) or acute uncomplicated pyelonephritis (AP).

02

Conditions studied

  • Complicated Urinary Tract Infection
  • Acute Pyelonephritis
  • cUTI
  • AP

Keywords

  • OP0595
  • nacubactam
  • Integral
03

In context

Pyelonephritis

79 studies on the registry are indexed under Pyelonephritis; 12 are open to participants now.

This study's enrollment of 614 is above the median of 175 across 62 interventional studies indexed under Pyelonephritis.

Browse Pyelonephritis studies →

Lead sponsor

Meiji Seika Pharma Co., Ltd. is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients at least18 years of age (or age of legal consent, whichever is older) at the time of obtaining and who can be hospitalized throughout the Treatment Period;
  2. Weight at most 140 kg;
  3. Expectation, in the opinion of the Investigator, that the patient's cUTI or AP will require treatment with at least 5 days of IV antibiotics;

Exclusion criteria

Exclusion Criteria:

  1. Has a known imipenem- and/or meropenem-resistant Gram-negative uropathogen (at least 10\^5 CFU/mL), isolated from study-qualifying urine culture; Note: If after randomization the susceptibility testing indicates resistance to imipenem and/or meropenem, the patient may remain on the study drug at the Investigator's discretion.
  2. Has known or suspected single or concurrent infection with Acinetobacter spp. or other organisms that are not adequately covered by the study drug (eg, concurrent viral, mycobacterial, or fungal infection) and needs to be managed with other anti-infectives; Note: Patients with qualifying pathogen coinfected with a Gram-positive pathogen may be administered narrow spectrum, open-label glycopeptide (eg, vancomycin), oxazolidinone (eg, linezolid), or daptomycin concomitantly with the study drug at the Investigator's discretion.
  3. Has only a known Gram-positive primary uropathogen (at least 10\^5 CFU/mL), isolated from study qualifying urine culture;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
614 participants (actual)

Study arms

  • Experimental
    co-administration of cefepime and nacubactam

    co-administration of 2 g cefepime and 1 g nacubactam q8h (60 min. infusion)

    Drug: co-administration of cefepime and nacubactam

  • Experimental
    co-administration of aztreonam and nacubactam

    co-administration of 2 g aztreonam and 1 g nacubactam q8h (60 min. infusion)

    Drug: co-administration of aztreonam and nacubactam

  • Active comparator
    imipenem/cilastatin

    combination of 1 g imipenem/1 g cilastatin q8h (60 min. infusion)

    Drug: imipenem/cilastatin

Interventions

  • Drugco-administration of cefepime and nacubactam

    Drug pages: Cefepime · Nacubactam

    2 g cefepime and 1 g nacubactam

  • Drugco-administration of aztreonam and nacubactam

    Drug pages: Aztreonam · Nacubactam

    2 g aztreonama and 1 g nacubactam

  • Drugimipenem/cilastatin

    Drug pages: Imipenem · Cilastatin

    1 g imipenem/1 g cilastatin

06

What researchers measure

Primary outcomes

  1. Proportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT) Population

    Composite clinical and microbiological success is defined as the composite clinical outcome of cure and the microbiological outcome of eradication.

    Time frame: TOC (Test of Cure visit): 7 [±2] days after EOT (end of treatment) [Day 10 to 23 after the start of treatment]

Secondary outcomes

  1. Proportion of Patients Who Achieve Composite Clinical and Microbiological Outcome

    Composite clinical and microbiological success is defined as the composite clinical outcome of cure and the microbiological outcome of eradication. Assessment of clinical outcome was based on Investigator's evaluation of the patient's clinical signs and symptoms, with cure defined as the complete resolution (or return to premorbid state) of the baseline signs and symptoms of cUTI or AP that were present at screening, such that no further antimicrobial therapy is warranted. Microbiological outcome was determined programmatically based on quantitative microbiological urine cultures, with eradication defined as the pathogen found at screening with 10\^5 CFU/ml or more reduced to less than 10\^3 CFU/ml. The results of subgroup analyses for only the two most frequent pathogens were shown because there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset.

    Time frame: Outcome measurements were assessed at various visits: EA (Earlly Assessment): Day4, EOT (End of Treatment): Day5 to Day14, TOC (Test of Cure visit): Day10 to Day 23, FUP (Follow-Up visit): Day17 to Day30

  2. Proportion of Patients With a Clinical Outcome of Cure

    Assessment of clinical outcome was based on Investigator's evaluation of the patient's clinical signs and symptoms, with cure defined as the complete resolution (or return to premorbid state) of the baseline signs and symptoms of cUTI or AP that were present at screening, such that no further antimicrobial therapy is warranted. The results of subgroup analyses for only the two most frequent pathogens were shown because there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset.

    Time frame: Outcome measurements were assessed at various visits: EA (Earlly Assessment): Day4, EOT (End of Treatment): Day5 to Day14, TOC (Test of Cure visit): Day10 to Day 23, FUP (Follow-Up visit): Day17 to Day30

  3. Proportion of Patients With a Microbiological Outcome of Eradication

    Microbiological outcome was determined programmatically based on quantitative microbiological urine cultures, with eradication defined as the pathogen found at screening with 10\^5 CFU/ml or more reduced to less than 10\^3 CFU/ml. The results of subgroup analyses for only the two most frequent pathogens were shown because there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset.

    Time frame: Outcome measurements were assessed at various visits: EA (Earlly Assessment): Day4, EOT (End of Treatment): Day5 to Day14, TOC (Test of Cure visit): Day10 to Day 23, FUP (Follow-Up visit): Day17 to Day30

  4. Proportion of Patients With a Clinical Outcome of Cure at TOC in Patients With Secondary Bacteremia at Baseline

    Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia.

    Time frame: TOC (Test of Cure visit): Day 10 to Day 23 after the start of treatment

  5. Proportion of Patients With a Microbiological Outcome of Eradication at TOC in Patients With Secondary Bacteremia at Baseline

    Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.

    Time frame: TOC (Test of Cure visit): Day 10 to Day 23 after the start of treatment

  6. Proportion of Patients Who Are Free From the Definition of Secondary Bacteremia AND a Clinical Outcome of Cure AND a Microbiological Outcome of Eradication From cUTI or AP at TOC in Patients With Secondary Bacteremia at Baseline

    Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. For cUTI/AP,Assessment is done by the same way as "Proportion of patients who achieve composite clinical and microbiological outcome". For secondary bacteremia, assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.

    Time frame: TOC (Test of Cure visit): Day 10 to Day 23 after the start of treatment

  7. Proportion of Patients Who Are Free From Secondary Bacteremia in Patients With Secondary Bacteremia at TOC

    Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.

    Time frame: TOC (Test of Cure visit): Day 10 to Day 23 after the start of treatment

07

Results

Posted Nov 25, 2025
Limitations and caveats
The analysis plan included subgroup analyses by pathogen for some secondary endpoints. However, there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset. Therefore, we present the results of subgroup analyses for only the two most frequent pathogens, as analyses for the others were considered statistically unreliable and clinically uninformative.

Participant flow

A total of 678 patients were screened at 66 sites in 9 countries and 614 patients were radomized.

Participant flow — Overall Study
MilestoneCefepime/NacubactamAztreonam/NacubactamImipenem/Cilastatin
Started309154151
Treated307152151
Completed study drug290147143
Completed284144139
Not completed251012
Withdrew: Adverse event611
Withdrew: Physician decision410
Withdrew: Withdrawal by subject323
Withdrew: Ineligibility after the start of the study410
Withdrew: Subject non-compliance404
Withdrew: Grew only a gram-negative organism resistant to imipenem and/or meropenem001
Withdrew: Pregnancy010
Withdrew: Required use of prohibited concomitant medications100
Withdrew: Significant prolongation of the qt/qtc interval010
Withdrew: Other reason333

Outcome measures

PrimaryProportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT) Population

Composite clinical and microbiological success is defined as the composite clinical outcome of cure and the microbiological outcome of eradication.

Time frame:
TOC (Test of Cure visit): 7 [±2] days after EOT (end of treatment) [Day 10 to 23 after the start of treatment]
Reported as:
Count of participants · Participants
Proportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT) Population
ParticipantsCefepime/NacubactamAztreonam/NacubactamImipenem/Cilastatin
Proportion of Patients Who Achieve Composite Clinical and Microbiological Success at TOC (Test of Cure Visit) in the Microbiological Modified Intent-to-Treat (m-MITT) Population1768164
Statistical analysis
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 21.3 · 95% CI 10.9 to 32.0Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 11.4 · 95% CI -1.2 to 23.7Miettinen-Nurminen confidence interval
SecondaryProportion of Patients Who Achieve Composite Clinical and Microbiological Outcome

Composite clinical and microbiological success is defined as the composite clinical outcome of cure and the microbiological outcome of eradication. Assessment of clinical outcome was based on Investigator's evaluation of the patient's clinical signs and symptoms, with cure defined as the complete resolution (or return to premorbid state) of the baseline signs and symptoms of cUTI or AP that were present at screening, such that no further antimicrobial therapy is warranted. Microbiological outcome was determined programmatically based on quantitative microbiological urine cultures, with eradication defined as the pathogen found at screening with 10\^5 CFU/ml or more reduced to less than 10\^3 CFU/ml. The results of subgroup analyses for only the two most frequent pathogens were shown because there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset.

Time frame:
Outcome measurements were assessed at various visits: EA (Earlly Assessment): Day4, EOT (End of Treatment): Day5 to Day14, TOC (Test of Cure visit): Day10 to Day 23, FUP (Follow-Up visit): Day17 to Day30
Reported as:
Count of participants · Participants
Proportion of Patients Who Achieve Composite Clinical and Microbiological Outcome
ParticipantsCefepime/NacubactamAztreonam/NacubactamImipenem/Cilastatin
Composite clinical and microbiological success at EA (Early Assessment visit)20111096
Composite clinical and microbiological success at EOT (End of Treatment visit)19910294
Composite clinical and microbiological success at FUP (Follow-up visit)1477365
Composite clinical and microbiological success at TOC by baseline pathogen: Escherichia coli1356245
Composite clinical and microbiological success at TOC by baseline pathogen: Klebsiella pneumoniae27119
Composite clinical and microbiological success at EOT by baseline pathogen: Escherichia coli1518166
Composite clinical and microbiological success at EOT by baseline pathogen: Klebsiella pneumoniae301016
Composite clinical and microbiological success at FUP by baseline pathogen: Escherichia coli1125744
Composite clinical and microbiological success at FUP by baseline pathogen: Klebsiella pneumoniae20911
Statistical analysis
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 2.5 · 95% CI -3.2 to 9.9Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 6.8 · 95% CI 1.1 to 14.0Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 3.5 · 95% CI -2.7 to 11.3Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 1.5 · 95% CI -6.6 to 10.0Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 6.8 · 95% CI -4.1 to 18.1Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 3.3 · 95% CI -9.5 to 16.0Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 24.1 · 95% CI 12.0 to 36.6Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 10.5 · 95% CI -4.2 to 24.9Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 28.1 · 95% CI 1.8 to 54.1Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 35.4 · 95% CI 1.1 to 61.6Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 6.4 · 95% CI -1.3 to 16.3Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 4.2 · 95% CI -5.6 to 14.7Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: -6.3 · 95% CI -20.3 to 13.9Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: -16.7 · 95% CI -45.4 to 5.2Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 11.2 · 95% CI -1.7 to 24.4Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 6.2 · 95% CI -8.7 to 20.9Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: -6.3 · 95% CI -31.9 to 23.1Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 6.3 · 95% CI -28.8 to 37.9Miettinen-Nurminen confidence interval
SecondaryProportion of Patients With a Clinical Outcome of Cure

Assessment of clinical outcome was based on Investigator's evaluation of the patient's clinical signs and symptoms, with cure defined as the complete resolution (or return to premorbid state) of the baseline signs and symptoms of cUTI or AP that were present at screening, such that no further antimicrobial therapy is warranted. The results of subgroup analyses for only the two most frequent pathogens were shown because there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset.

Time frame:
Outcome measurements were assessed at various visits: EA (Earlly Assessment): Day4, EOT (End of Treatment): Day5 to Day14, TOC (Test of Cure visit): Day10 to Day 23, FUP (Follow-Up visit): Day17 to Day30
Reported as:
Count of participants · Participants
Proportion of Patients With a Clinical Outcome of Cure
ParticipantsCefepime/NacubactamAztreonam/NacubactamImipenem/Cilastatin
Clinical outcome of cure at EA942
Clinical outcome of cure at EOT204106100
Clinical outcome of cure at TOC19510392
Clinical outcome of cure at FUP1889889
Clinical outcome of cure at EA by baseline pathogen: Escherichia coli531
Clinical outcome of cure at EA by baseline pathogen: Klebsiella pneumoniae210
Clinical outcome of cure at EOT by baseline pathogen: Escherichia coli1558471
Clinical outcome of cure at EOT by baseline pathogen: Klebsiella pneumoniae311116
Clinical outcome of cure at TOC by baseline pathogen: Escherichia coli1488267
Clinical outcome of cure at TOC by baseline pathogen: Klebsiella pneumoniae301113
Clinical outcome of cure at FUP by baseline pathogen: Escherichia coli1437862
Clinical outcome of cure at FUP by baseline pathogen: Klebsiella pneumoniae281115
Statistical analysis
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 2.3 · 95% CI -2.8 to 6.3Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 1.7 · 95% CI -3.5 to 7.2Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 0.1 · 95% CI -4.6 to 6.4Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: -0.6 · 95% CI -7.1 to 6.0Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 3.5 · 95% CI -3.3 to 11.8Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 4.3 · 95% CI -3.9 to 13.0Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 3.1 · 95% CI -4.5 to 12.1Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 2.7 · 95% CI -6.6 to 12.3Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 1.8 · 95% CI -4.2 to 6.0Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 2.1 · 95% CI -4.1 to 8.3Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 6.3 · 95% CI -13.9 to 20.3Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 8.3 · 95% CI -12.6 to 36.0Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 2.3 · 95% CI -3.5 to 10.5Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 1.0 · 95% CI -6.9 to 9.6Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: -3.1 · 95% CI -15.9 to 16.8Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: -8.3 · 95% CI -36.0 to 12.6Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 3.2 · 95% CI -4.5 to 13.1Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 4.0 · 95% CI -5.3 to 14.2Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 12.5 · 95% CI -6.0 to 38.0Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 10.4 · 95% CI -20.5 to 37.3Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 6.7 · 95% CI -2.6 to 17.8Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 6.1 · 95% CI -5.0 to 17.8Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: -6.3 · 95% CI -23.6 to 17.6Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: -2.1 · 95% CI -30.9 to 22.3Miettinen-Nurminen confidence interval
SecondaryProportion of Patients With a Microbiological Outcome of Eradication

Microbiological outcome was determined programmatically based on quantitative microbiological urine cultures, with eradication defined as the pathogen found at screening with 10\^5 CFU/ml or more reduced to less than 10\^3 CFU/ml. The results of subgroup analyses for only the two most frequent pathogens were shown because there were a large number of pathogen types, most of which were rare and sparsely represented in the dataset.

Time frame:
Outcome measurements were assessed at various visits: EA (Earlly Assessment): Day4, EOT (End of Treatment): Day5 to Day14, TOC (Test of Cure visit): Day10 to Day 23, FUP (Follow-Up visit): Day17 to Day30
Reported as:
Count of participants · Participants
Proportion of Patients With a Microbiological Outcome of Eradication
ParticipantsCefepime/NacubactamAztreonam/NacubactamImipenem/Cilastatin
Microbiological outcome of eradication at EA20511297
Microbiological outcome of eradication at EOT20310595
Microbiological outcome of eradication at TOC1848367
Microbiological outcome of eradication at FUP1577568
Microbiological outcome of eradication at EA by baseline pathogen: Escherichia coli1558971
Microbiological outcome of eradication at EA by baseline pathogen: Klebsiella pneumoniae301213
Microbiological outcome of eradication at EOT by baseline pathogen: Escherichia coli1548367
Microbiological outcome of eradication at EOT by baseline pathogen: Klebsiella pneumoniae301116
Microbiological outcome of eradication at TOC by baseline pathogen: Escherichia coli1416347
Microbiological outcome of eradication at TOC by baseline pathogen: Klebsiella pneumoniae271110
Microbiological outcome of eradication at FUP by baseline pathogen: Escherichia coli1195846
Microbiological outcome of eradication at FUP by baseline pathogen: Klebsiella pneumoniae22912
Statistical analysis
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 3.4 · 95% CI -1.7 to 10.5Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 7.6 · 95% CI 3.9 to 14.3Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 4.4 · 95% CI -1.3 to 11.9Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 3.3 · 95% CI -4.2 to 11.2Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 22.2 · 95% CI 12.2 to 32.7Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 10.3 · 95% CI -2.0 to 22.5Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 8.6 · 95% CI -2.0 to 19.7Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 2.2 · 95% CI -10.4 to 14.8Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 2.3 · 95% CI -3.5 to 10.5Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 6.6 · 95% CI 2.3 to 14.5Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 12.5 · 95% CI -6.0 to 38.0Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 18.8 · 95% CI -8.3 to 43.5Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 6.9 · 95% CI -0.1 to 16.5Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 5.1 · 95% CI -3.9 to 15.1Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: -6.3 · 95% CI -20.3 to 13.9Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: -8.3 · 95% CI -36.0 to 12.6Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 25.2 · 95% CI 13.5 to 37.5Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 8.9 · 95% CI -5.5 to 23.3Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 21.9 · 95% CI -3.4 to 48.5Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 29.2 · 95% CI -4.4 to 56.0Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 12.9 · 95% CI 0.3 to 25.9Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 4.6 · 95% CI -10.1 to 19.3Miettinen-Nurminen confidence interval
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: -6.3 · 95% CI -30.4 to 22.6Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 0.0 · 95% CI -34.0 to 31.5Miettinen-Nurminen confidence interval
SecondaryProportion of Patients With a Clinical Outcome of Cure at TOC in Patients With Secondary Bacteremia at Baseline

Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia.

Time frame:
TOC (Test of Cure visit): Day 10 to Day 23 after the start of treatment
Reported as:
Count of participants · Participants
Proportion of Patients With a Clinical Outcome of Cure at TOC in Patients With Secondary Bacteremia at Baseline
ParticipantsCefepime/NacubactamAztreonam/NacubactamImipenem/Cilastatin
Proportion of Patients With a Clinical Outcome of Cure at TOC in Patients With Secondary Bacteremia at Baseline1286
Statistical analysis
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 20.0 · 95% CI -16.0 to 54.3Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 28.9 · 95% CI -13.0 to 62.1Miettinen-Nurminen confidence interval
SecondaryProportion of Patients With a Microbiological Outcome of Eradication at TOC in Patients With Secondary Bacteremia at Baseline

Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.

Time frame:
TOC (Test of Cure visit): Day 10 to Day 23 after the start of treatment
Reported as:
Count of participants · Participants
Proportion of Patients With a Microbiological Outcome of Eradication at TOC in Patients With Secondary Bacteremia at Baseline
ParticipantsCefepime/NacubactamAztreonam/NacubactamImipenem/Cilastatin
Proportion of Patients With a Microbiological Outcome of Eradication at TOC in Patients With Secondary Bacteremia at Baseline1286
Statistical analysis
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 20.0 · 95% CI -16.0 to 54.3Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 28.9 · 95% CI -13.0 to 62.1Miettinen-Nurminen confidence interval
SecondaryProportion of Patients Who Are Free From the Definition of Secondary Bacteremia AND a Clinical Outcome of Cure AND a Microbiological Outcome of Eradication From cUTI or AP at TOC in Patients With Secondary Bacteremia at Baseline

Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. For cUTI/AP,Assessment is done by the same way as "Proportion of patients who achieve composite clinical and microbiological outcome". For secondary bacteremia, assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.

Time frame:
TOC (Test of Cure visit): Day 10 to Day 23 after the start of treatment
Reported as:
Count of participants · Participants
Proportion of Patients Who Are Free From the Definition of Secondary Bacteremia AND a Clinical Outcome of Cure AND a Microbiological Outcome of Eradication From cUTI or AP at TOC in Patients With Secondary Bacteremia at Baseline
ParticipantsCefepime/NacubactamAztreonam/NacubactamImipenem/Cilastatin
Proportion of Patients Who Are Free From the Definition of Secondary Bacteremia AND a Clinical Outcome of Cure AND a Microbiological Outcome of Eradication From cUTI or AP at TOC in Patients With Secondary Bacteremia at Baseline1142
Statistical analysis
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 53.3 · 95% CI 12.8 to 78.1Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 24.4 · 95% CI -18.4 to 60.5Miettinen-Nurminen confidence interval
SecondaryProportion of Patients Who Are Free From Secondary Bacteremia in Patients With Secondary Bacteremia at TOC

Patients with isolation of a gram-negative bacteria from at least 1 blood culture at baseline and this isolated pathogen is also identified from the site of infection and signs and symptoms of secondary bacteremia were determined programmatically as secondary bacteremia. Assessment of clinical outcome was based on signs and symptoms, with cure defined as complete resolution or significant improvement of the baseline signs and symptoms of secondary bacteremia. Microbiological outcome will be determined programmatically based on blood cultures, with eradication defined as the pathogen found at screening is negative in blood culture.

Time frame:
TOC (Test of Cure visit): Day 10 to Day 23 after the start of treatment
Reported as:
Count of participants · Participants
Proportion of Patients Who Are Free From Secondary Bacteremia in Patients With Secondary Bacteremia at TOC
ParticipantsCefepime/NacubactamAztreonam/NacubactamImipenem/Cilastatin
Proportion of Patients Who Are Free From Secondary Bacteremia in Patients With Secondary Bacteremia at TOC1286
Statistical analysis
  • Cefepime/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 20.0 · 95% CI -16.0 to 54.3Miettinen-Nurminen confidence interval
  • Aztreonam/Nacubactam vs Imipenem/Cilastatin · Difference in success proportion: 28.9 · 95% CI -13.0 to 62.1Miettinen-Nurminen confidence interval

Adverse events

Collected over Up to follow-up visit (maximum Day 30). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cefepime/Nacubactam1/306 (0.3%)6/306 (2%)100/306 (32.7%)
Aztreonam/Nacubactam0/152 (0%)4/152 (2.6%)45/152 (29.6%)
Imipenem/Cilastatin0/150 (0%)5/150 (3.3%)65/150 (43.3%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventCefepime/NacubactamAztreonam/NacubactamImipenem/Cilastatin
PyrexiaGeneral disorders0/3060/1522/150
Urinary tract infectionInfections and infestations1/3062/1521/150
OrchitisInfections and infestations0/3060/1521/150
ChillsGeneral disorders0/3060/1521/150
HyperthermiaGeneral disorders0/3060/1521/150
Renal failureRenal and urinary disorders0/3060/1521/150
Acute kidney injuryRenal and urinary disorders0/3061/1520/150
Biliary colicHepatobiliary disorders0/3061/1520/150
COVID-19Infections and infestations1/3060/1520/150
Disease progressionGeneral disorders1/3060/1520/150
Most frequent other events
Showing 10 of 12
Most frequent other events
EventCefepime/NacubactamAztreonam/NacubactamImipenem/Cilastatin
Any AEs with frequency less than 2%General disorders42/30613/15217/150
NauseaGastrointestinal disorders5/3061/15210/150
HeadacheNervous system disorders10/3068/1526/150
Asymptomatic bacteriuriaInfections and infestations3/3067/1525/150
DiarrhoeaGastrointestinal disorders14/3063/1526/150
VomitingGastrointestinal disorders2/3061/1525/150
ConstipationGastrointestinal disorders6/3063/1524/150
RashSkin and subcutaneous tissue disorders2/3062/1524/150
Abdominal pain upperGastrointestinal disorders1/3061/1523/150
PyrexiaGeneral disorders4/3062/1523/150

Baseline characteristics

m-MITT population

Age, Categorical
Age, Categorical(Participants)Cefepime/NacubactamAztreonam/NacubactamImipenem/CilastatinTotal
<=18 years0000
Between 18 and 65 years994241182
>=65 years1157064249
Sex: Female, Male
Sex: Female, Male(Participants)Cefepime/NacubactamAztreonam/NacubactamImipenem/CilastatinTotal
Female1035149203
Male1116156228
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cefepime/NacubactamAztreonam/NacubactamImipenem/CilastatinTotal
Race, Customized — Asian-Japanese126523
Race, Customized — Asian-Chinese239739
Race, Customized — Asian-other0101
Race, Customized — White1799693368
Age, Continuous
Age, Continuous(years)Cefepime/NacubactamAztreonam/NacubactamImipenem/CilastatinTotal
Mean63.6 ± 14.8366.4 ± 14.0465.5 ± 15.5764.8 ± 14.83
Age, Customized
Age, Customized(Participants)Cefepime/NacubactamAztreonam/NacubactamImipenem/CilastatinTotal
Age, Customized — <65 years994241182
Age, Customized — 65 - 74 Years623632130
Age, Customized — >=75 years533432119
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cefepime/NacubactamAztreonam/NacubactamImipenem/CilastatinTotal
Ethnicity, Customized — Hispanic or Latino1023
Ethnicity, Customized — Not Hispanic or Latino212112103427
Ethnicity, Customized — Unknown1001
Region of Enrollment
Region of Enrollment(Participants)Cefepime/NacubactamAztreonam/NacubactamImipenem/CilastatinTotal
Japan126523
China2310740
Other1799693368
Primary infection type collected in eCRF
Primary infection type collected in eCRF(Participants)Cefepime/NacubactamAztreonam/NacubactamImipenem/CilastatinTotal
Complicated Urinary Tract Infection (cUTI)1377673286
Acute Uncomplicated Pyelonephritis (AP)773632145

4 further baseline measures are reported on the registry.

08

Study locations

61 sites
  • Meiji Research Site
    Pleven, Bulgaria
  • Meiji Research Site
    Rousse, Bulgaria
  • Meiji Research Site
    Silistra, Bulgaria
  • Meiji Research Site
    Sofia, Bulgaria
  • Meiji Research Site
    Beijing, China
  • Meiji Research Site
    Changchun, China
  • Meiji Research Site
    Chongqing, China
  • Meiji Research Site
    Fuyang, China
  • Meiji Research Site
    Ganzhou, China
  • Meiji Research Site
    Huaian, China
  • Meiji Research Site
    Huzhou, China
  • Meiji Research Site
    Nanchang, China
  • Meiji Research Site
    Nanning, China
  • Meiji Research Site
    Quanzhou, China
  • Meiji Research Site
    Shanghai, China
  • Meiji Research Site
    Shantou, China
  • Meiji Research Site
    Shijiazhuang, China
  • Meiji Research Site
    Taian, China
  • Meiji Research Site
    Tianjin, China
  • Meiji Research Site
    Xuancheng, China
  • Meiji Research Site
    Yunnan, China
  • Meiji Research Site
    Zhejiang, China
  • Meiji Research Site
    Zhengzhou, China
  • Meiji Research Site
    Hradec Králové, Czechia
  • Meiji Research Site
    Liberec, Czechia
  • Meiji Research Site
    Prague, Czechia
  • Meiji Research Site
    Ústí nad Labem, Czechia
  • Meiji Research Site
    Meegomäe, Võrumaa, Estonia
  • Meiji Research Site
    Kohtla-Järve, Estonia
  • Meiji Research Site
    Tallinn, Estonia
  • Meiji Research Site
    Tartu, Estonia
  • Meiji Research Site
    Kutaisi, Georgia
  • Meiji Research Site
    Rustavi, Georgia
  • Meiji Research Site
    Tbilisi, Georgia
  • Meiji Research Site
    Fukuyama, Japan
  • Meiji Research Site
    Gifu, Japan
  • Meiji Research Site
    Ibaraki-Town, Higashiibaraki-County, Japan
  • Meiji Research Site
    Iwakuni, Japan
  • Meiji Research Site
    Kanazawa, Japan
  • Meiji Research Site
    Kawachi-Nagano, Japan
  • Meiji Research Site
    Kofu, Japan
  • Meiji Research Site
    Kumamoto, Japan
  • Meiji Research Site
    Matsumoto, Japan
  • Meiji Research Site
    Mizumaki-Town, Onga-County, Japan
  • Meiji Research Site
    Nagasaki, Japan
  • Meiji Research Site
    Nankoku, Japan
  • Meiji Research Site
    Ōita, Japan
  • Meiji Research Site
    Ōtake, Japan
  • Meiji Research Site
    Sagamihara, Japan
  • Meiji Research Site
    Sapporo, Japan
  • Meiji Research Site
    Shinjuku-ku, Japan
  • Meiji Research Site
    Toyota, Japan
  • Meiji Research Site
    Ueda, Japan
  • Meiji Research Site
    Yokohama, Japan
  • Meiji Research Site
    Riga, Latvia
  • Meiji Research Site
    Valmiera, Latvia
  • Meiji Research Site
    Kaunas, Lithuania
  • Meiji Research Site
    Vilnius, Lithuania
  • Meiji Research Site
    Galanta, Slovakia
  • Meiji Research Site
    Rimavská Sobota, Slovakia
  • Meiji Research Site
    Svidník, Slovakia
09

References and documents

Publications

  • Takahashi S, Tateda K, Yanagihara K, Huang H, Doi Y, Yasuda M, Matsumoto K, Sumiya M, Takaya R, Suwada K, Kamiyabu S, Sasagawa Y, Minamida T, Kato S, Kondo K, Naruse T, Mikamo H. Efficacy and safety of cefepime-nacubactam and aztreonam-nacubactam compared with imipenem-cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial. Lancet. 2026 May 16;407(10542):1929-1940. doi: 10.1016/S0140-6736(26)00596-9. PubMed 42134354 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Nov 2024, 17 months.

Results were first posted in Nov 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2023
First posted
Jun 5, 2023
StartActual
May 23, 2023
Primary completionActual
Nov 22, 2024
CompletionActual
Nov 26, 2024
Results first posted
Nov 25, 2025
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05887908
Lead sponsor
Meiji Seika Pharma Co., Ltd.
Responsible party
Sponsor
First posted
Jun 5, 2023
Start date
May 23, 2023
Primary completion
Nov 22, 2024
Completion
Nov 26, 2024
Results posted
Nov 25, 2025
Last update
Dec 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cefepime · Nacubactam · Aztreonam

Start the discussion